Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00987766 |
Recruitment Status :
Completed
First Posted : October 1, 2009
Last Update Posted : July 2, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine hydrochloride and oxaliplatin together with erlotinib hydrochloride may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with gemcitabine hydrochloride and oxaliplatin in treating patients with advanced biliary tract cancer, pancreatic cancer, duodenal cancer, or ampullary cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Extrahepatic Bile Duct Cancer Gallbladder Cancer Liver Cancer Pancreatic Cancer Periampullary Adenocarcinoma Small Intestine Cancer | Drug: erlotinib hydrochloride Drug: gemcitabine hydrochloride Drug: oxaliplatin Other: laboratory biomarker analysis | Phase 1 |
OBJECTIVES:
Primary
- To determine the maximum tolerated dose and the recommended phase II dose of erlotinib hydrochloride in combination with gemcitabine hydrochloride and oxaliplatin in patients with advanced biliary tract cancer, pancreatic cancer, duodenal cancer, or ampullary cancer.
Secondary
- To describe any antitumor activity associated with this treatment regimen when given during the dose-escalation and expanded-cohort portions of this study.
- To evaluate e-cadherin, vimentin, fibronectin, amphiregulin, and Kras status in the tumors and assess their relationship to response.
OUTLINE: This is a multicenter, dose-escalation study of erlotinib hydrochloride.
Patients receive gemcitabine hydrochloride IV on day 1, oxaliplatin IV over 2 hours on day 2, and oral erlotinib hydrochloride once daily on days 3-8. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Tumor tissue samples are collected for biomarker and other analysis.
After completion of study treatment, patients are followed up for 30 days.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 28 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. |
Study Start Date : | November 2009 |
Actual Primary Completion Date : | July 2013 |
Actual Study Completion Date : | October 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment
Gemcitabine + Oxaliplatin + Erlotinib
|
Drug: erlotinib hydrochloride
Taken daily by mouth for 6 days every other week. Drug: gemcitabine hydrochloride Given through a vein in the arm 1 time every other week. Drug: oxaliplatin Given through a vein in the arm 1 time every other week. Other: laboratory biomarker analysis Blood and tissue collection. |
- Maximum tolerated dose and recommended phase II dose of erlotinib hydrochloride in combination with gemcitabine hydrochloride and oxaliplatin [ Time Frame: 28 days ]
- Antitumor activity [ Time Frame: 30 days after completing treatment. ]
- E-cadherin, vimentin, fibronectin, amphiregulin, and Kras status in the tumors and their relationship to response [ Time Frame: 30 days after completing treatment. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Only advanced carcinomas defined as unresectable or metastatic that are histologically or cytologically confirmed to be biliary tract, pancreas, duodenal, or ampullary carcinomas will be included.
- Dose-escalation: Patients > 18 years of age with biopsy-confirmed advanced biliary tract adenocarcinoma, pancreas cancer, duodenal cancer, or ampullary cancer
- MTD expansion cohort: Patients > 18 years of age with biopsy-confirmed advanced biliary tract adenocarcinoma only.
- No prior chemotherapy or prior EGF receptor inhibitor therapy
- Measurable tumor by imaging examination
- Performance status (PS) 0-2 on the ECOG performance scale
- Have pretreatment bilirubin<2.5x upper limit of normal (ULN), serum creatinine<1.5x ULN, AST and ALT <2.5xULN or in the presence of liver metastasis <5xULN, neutrophils>1500, platelets>100K, hemoglobin >9 g/dL
- Patients - both males and females - with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.
- Have the ability to understand the requirements of the study and provide informed consent
Exclusion Criteria:
- CNS metastases
- Uncontrolled infection
- Pregnant or nursing women may not participate.
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.
- Psychiatric illness that would prevent understanding the nature of the investigational therapy and complying with protocol requirements
- Patients with > grade 2 neuropathy
- Patients with > grade 2 uncontrolled nausea and vomiting despite antiemetics
- Any concurrent medical condition that, in the judgment of the investigator, would make the patient an inappropriate candidate for study enrollment
- Prior chemotherapy or EGFR inhibitor

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00987766
United States, Tennessee | |
Vanderbilt-Ingram Cancer Center | |
Nashville, Tennessee, United States, 37232-6838 |
Principal Investigator: | Laura Goff, MD | Vanderbilt-Ingram Cancer Center |
Responsible Party: | Laura W. Goff, MD, Assistant Professor of Medicine; Associate Director, Hematology/Oncology Fellowship Program; Medical Oncologist, Vanderbilt-Ingram Cancer Center |
ClinicalTrials.gov Identifier: | NCT00987766 |
Other Study ID Numbers: |
VICC GI 0906 P30CA068485 ( U.S. NIH Grant/Contract ) |
First Posted: | October 1, 2009 Key Record Dates |
Last Update Posted: | July 2, 2017 |
Last Verified: | June 2017 |
advanced adult primary liver cancer stage III pancreatic cancer stage IV pancreatic cancer periampullary adenocarcinoma small intestine adenocarcinoma |
adenocarcinoma of the extrahepatic bile duct adenocarcinoma of the gallbladder unresectable extrahepatic bile duct cancer unresectable gallbladder cancer |
Adenocarcinoma Pancreatic Neoplasms Liver Neoplasms Biliary Tract Neoplasms Gallbladder Neoplasms Bile Duct Neoplasms Cholangiocarcinoma Intestinal Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms |
Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Liver Diseases Biliary Tract Diseases Gallbladder Diseases Bile Duct Diseases Gastrointestinal Neoplasms Gastrointestinal Diseases Intestinal Diseases Gemcitabine Oxaliplatin Erlotinib Hydrochloride Antimetabolites, Antineoplastic Antimetabolites |